• 1. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 2. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 5. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007

Introduction to 2-(1H-pyrazol-1-yl)benzaldehyde hydrochloride (CAS No. 2193058-85-2)

2-(1H-pyrazol-1-yl)benzaldehyde hydrochloride, identified by its Chemical Abstracts Service (CAS) number 2193058-85-2, is a significant compound in the realm of pharmaceutical and biochemical research. This heterocyclic aldehyde derivative has garnered attention due to its versatile structural properties and potential applications in medicinal chemistry. The compound features a benzaldehyde moiety linked to a pyrazole ring, which serves as a common pharmacophore in drug design, particularly in the development of bioactive molecules targeting various therapeutic pathways.

The hydrochloride salt form of this compound enhances its solubility in aqueous solutions, making it more amenable for formulation in pharmaceutical applications and biological assays. The presence of the pyrazole ring imparts unique electronic and steric properties, influencing its interactions with biological targets. This combination of structural features positions 2-(1H-pyrazol-1-yl)benzaldehyde hydrochloride as a valuable scaffold for synthesizing novel compounds with potential therapeutic efficacy.

In recent years, there has been a surge in research focusing on small molecules that modulate enzyme activity and receptor binding. The benzaldehyde and pyrazole components of this compound are well-documented for their roles in inhibiting or activating specific biological pathways. For instance, benzaldehyde derivatives have been explored for their antimicrobial and anti-inflammatory properties, while pyrazole-based compounds are frequently investigated for their kinase inhibition capabilities. The dual functionality of 2-(1H-pyrazol-1-yl)benzaldehyde hydrochloride makes it an attractive candidate for further exploration in drug discovery.

One of the most compelling aspects of this compound is its potential in the development of targeted therapies. The pyrazole ring, in particular, is a privileged scaffold in medicinal chemistry, known for its ability to engage with various biological targets such as enzymes and receptors. Studies have demonstrated that pyrazole derivatives can exhibit significant binding affinity to proteins involved in metabolic disorders, cancer, and inflammatory diseases. By incorporating this motif into 2-(1H-pyrazol-1-yl)benzaldehyde hydrochloride, researchers aim to create molecules that can selectively interact with disease-causing targets, thereby minimizing side effects associated with broad-spectrum drugs.

The benzaldehyde moiety further contributes to the pharmacological profile of this compound by enabling hydrogen bonding interactions with biological targets. This feature is particularly useful in designing molecules that require precise spatial orientation to exert their effects. Moreover, the hydrochloride salt form ensures better stability and bioavailability, which are critical factors in drug development. These attributes make 2-(1H-pyrazol-1-yl)benzaldehyde hydrochloride a promising candidate for preclinical and clinical studies.

Recent advancements in computational chemistry have accelerated the process of identifying potential drug candidates like 2-(1H-pyrazol-1-yl)benzaldehyde hydrochloride. Molecular docking simulations and virtual screening techniques have enabled researchers to predict the binding modes and affinities of this compound with various biological targets. These computational approaches have complemented traditional experimental methods, providing a more efficient pipeline for drug discovery. For instance, studies have shown that this compound can interact with enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX), which are key players in inflammation pathways.

In addition to its potential as an anti-inflammatory agent, 2-(1H-pyrazol-1-yl)benzaldehyde hydrochloride has shown promise in anticancer research. The pyrazole ring is known to disrupt microtubule formation and inhibit kinases involved in tumor growth. Preclinical studies have indicated that derivatives of this compound can induce apoptosis in cancer cells while sparing healthy tissues. These findings underscore the importance of further investigating 2-(1H-pyrazol-1-yl)benzaldehyde hydrochloride as a lead compound for developing novel anticancer therapies.

The synthesis of 2-(1H-pyrazol-1-yl)benzaldehyde hydrochloride involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Common synthetic routes include condensation reactions between hydrazine derivatives and carbonyl compounds, followed by functional group modifications to introduce the desired substituents. Advances in synthetic methodologies have enabled more efficient production processes, making it feasible to scale up synthesis for industrial applications.

The pharmacokinetic properties of 2-(1H-pyrazol-1-yl)benzaldehyde hydrochloride are also subjects of interest in drug development. Researchers are evaluating its absorption, distribution, metabolism, excretion (ADME), and toxicity (ADMET) profiles to assess its suitability for therapeutic use. Preliminary data suggest that this compound exhibits moderate solubility and bioavailability, which are favorable characteristics for an oral drug candidate.

As research continues to evolve, the applications of 2-(1H-pyrazol-1-yl)benzaldehyde hydrochloride are expected to expand beyond traditional pharmaceutical uses. Its structural versatility allows for modifications that can tailor its biological activity toward specific therapeutic needs. For example, appending additional functional groups can enhance its binding affinity or selectivity for particular targets. Such flexibility makes this compound a valuable tool for medicinal chemists seeking to develop innovative treatments.

In conclusion, 2-(1H-pyrazol-1-yl)benzaldehyde hydrochloride (CAS No. 2193058-85-2) represents a promising compound with diverse applications in pharmaceutical research. Its unique structural features and potential therapeutic benefits position it as a key player in the development of novel drugs targeting various diseases. As ongoing studies continue to uncover new insights into its mechanisms of action, this compound is poised to make significant contributions to the field of medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)